ANIP Stock: What's Driving Cortrophin Gel's 2026 Surge

Cortrophin Gel is reshaping ANI Pharmaceuticals into a specialty-driven growth story, with 2026 revenue guidance signaling another major leap.

Zacks Investment Research • 15 hours ago

ANIP Valuation: Does 9.8x Forward P/E Offer Upside?

ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales.

Zacks Investment Research • 15 hours ago

ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook

ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.

Zacks Investment Research • 15 hours ago

ANI Pharmaceuticals (ANIP) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • May 13, 2026

ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised

ANI Pharmaceuticals tops Q1 estimates as Cortrophin Gel sales climb 42%, prompting it to raise the 2026 revenue, EBITDA and EPS outlook.

Zacks Investment Research • May 11, 2026

ANI Pharmaceuticals Q1 Earnings Call Highlights

ANI Pharmaceuticals NASDAQ: ANIP reported first-quarter 2026 results that management said show continued progress in its effort to “accelerat[e] our transformation into a leading rare disease company,” led by growth in Cortrophin Gel and ILUVIEN, contributions from a new intellectual property licensing transaction with Harmony Biosciences, and steady generics performance.

MarketBeat • May 8, 2026

ANI Pharmaceuticals, Inc. (ANIP) Q1 2026 Earnings Call Transcript

ANI Pharmaceuticals, Inc. (ANIP) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance

PRINCETON, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended March 31, 2026.

GlobeNewsWire • May 8, 2026

ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates

ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.7 per share a year ago.

Zacks Investment Research • May 8, 2026

ANI (ANIP) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • May 8, 2026